A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

被引：0
|
作者：
Alexander C. J. van Akkooi
Sebastian Haferkamp
Sophie Papa
Viola Franke
Andreas Pinter
Carsten Weishaupt
Margit A. Huber
Carmen Loquai
Erika Richtig
Priya Gokani
Katarina Öhrling
Karly S. Louie
Peter Mohr
机构：
[1] Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL),Department of Surgical Oncology
[2] University Hospital Regensburg,Department of Dermatology
[3] Guy’s and St. Thomas’ NHS Foundation Trust,Department of Medical Oncology
[4] University Hospital Frankfurt,Department of Dermatology, Venereology and Allergology
[5] University Hospital of Muenster,Department of Dermatology
[6] Ulm University,Department of Dermatology and Allergic Diseases
[7] University Medical Center Mainz,Department of Dermatology
[8] Medical University of Graz,Department of Dermatology
[9] Amgen Ltd,undefined
[10] Amgen Europe GmbH,undefined
[11] Amgen Ltd,undefined
[12] Elbe-Klinikum Buxtehude,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Immunotherapy; Injectable; Lesion; Melanoma; Oncolytic; Real-world study; Skin cancer; T-VEC; Talimogene laherparepvec; Tumour;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1245 / 1262
页数：17
相关论文
共 38 条
  • [1] A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries
    van Akkooi, Alexander C. J.
    Haferkamp, Sebastian
    Papa, Sophie
    Franke, Viola
    Pinter, Andreas
    Weishaupt, Carsten
    Huber, Margit A.
    Loquai, Carmen
    Richtig, Erika
    Gokani, Priya
    Ohrling, Katarina
    Louie, Karly S.
    Mohr, Peter
    ADVANCES IN THERAPY, 2021, 38 (02) : 1245 - 1262
  • [2] Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
    Peter Mohr
    Sebastian Haferkamp
    Andreas Pinter
    Carsten Weishaupt
    Margit A. Huber
    Gerald Downey
    Katarina Öhrling
    Carmen Loquai
    Karly S. Louie
    Advances in Therapy, 2019, 36 : 101 - 117
  • [3] Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey
    Mohr, Peter
    Haferkamp, Sebastian
    Pinter, Andreas
    Weishaupt, Carsten
    Huber, Margit A.
    Downey, Gerald
    OEhrling, Katarina
    Loquai, Carmen
    Louie, Karly S.
    ADVANCES IN THERAPY, 2019, 36 (01) : 101 - 117
  • [4] Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial
    R. Dummer
    D. E. Gyorki
    J. Hyngstrom
    A. C. Berger
    R. Conry
    L. Demidov
    A. Sharma
    S. A. Treichel
    H. Radcliffe
    K. S. Gorski
    A. Anderson
    E. Chan
    M. Faries
    M. I. Ross
    Nature Medicine, 2021, 27 : 1789 - 1796
  • [5] Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis
    Stahlie, Emma H. A.
    Mulder, Evalyn E. A. P.
    Reijers, Sophie
    Balduzzi, Sara
    Zuur, Charlotte L.
    Klop, Willem M. C.
    van der Hiel, Bernies
    Van de Wiel, Bart A.
    Wouters, Michel W. J. M.
    Schrage, Yvonne M.
    Houdt, Winan J. van
    Grunhagen, Dirk J.
    Akkooi, Alexander C. J. van
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 175
  • [6] Real-world use of talimogene laherparepvec in Germany: a retrospective observational study using a prescription database
    Louie, Karly S.
    Banks, Victoria
    Scholz, Florian
    Richter, Hartmut
    Ohrling, Katarina
    Mohr, Peter
    Haferkamp, Sebastian
    FUTURE ONCOLOGY, 2020, 16 (08) : 317 - 328
  • [7] Timing of onset and resolution of adverse events in patients with unresectable stage IIIB-IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
    Andtbacka, R.
    Kaufman, H.
    Harrington, K.
    Middleton, M.
    Melcher, A.
    Ottensmeier, C.
    Safaei, R.
    Downey, G.
    He, P.
    Collichio, F.
    MELANOMA RESEARCH, 2016, 26 : E36 - E37
  • [8] Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial
    Harrington, Kevin J.
    Andtbacka, Obert H. I.
    Collichio, Frances
    Downey, Gerald
    Chen, Lisa
    Szabo, Zsolt
    Kaufman, Howard L.
    ONCOTARGETS AND THERAPY, 2016, 9 : 7081 - 7093
  • [9] MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)
    Ribas, A.
    Chesney, J.
    Long, G. V.
    Kirkwood, J. M.
    Dummer, R.
    Puzanov, I.
    Hoeller, C.
    Gajewski, T. F.
    Gutzmer, R.
    Rutkowski, P.
    Demidov, L.
    Arenberger, P.
    Shin, S. J.
    Ferrucci, P. F.
    Diede, S. J.
    Anderson, J. R.
    Treichel, S.
    Chan, E.
    Hodi, F. S.
    Gogas, H. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S868 - S869
  • [10] Relationship between talimogene laherparepvec and intratumoral CD8+density in patients with unresectable stage IIIB-IVM1c melanoma: Interim efficacy, safety and biomarker results of a Phase 2 study
    Malvehy, J.
    Samoylenko, I.
    Schadendorf, D.
    Gutzmer, R.
    Grob, J. -J.
    Sacco, J.
    Gorski, K. S.
    Pickett, C. A.
    Liu, K.
    Gogas, H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 39 - 40
1234